A Phase 4 interventional study of Nicotine Pouches and Mini Nicotine lozenges in Smoker and Smoking Cessation, sponsored by University of Wisconsin, Madison. Recruiting at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-06-22.
Sponsored by University of Wisconsin, Madison · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Smoking Cessation by University of Wisconsin, Madison — 3 open to participants now, 3 under way, none of them phase 3. Smoking Cessation · University of Wisconsin, Madison.
Among the 33 studies in Smoking Cessation by University of Wisconsin, Madison, this one is the 20th largest by planned enrollment of the 32 interventional ones that give a count, is the only one that started in 2025, is one of 18 in phase 4, and was the 31st registered.
1,583 studies on the registry are indexed under Smoking Cessation; 196 are open to participants now.
Browse Smoking Cessation studies →3 of the 33 studies in Smoking Cessation by University of Wisconsin, Madison are open now, in 1 country. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 21+ · Healthy volunteers
University of Wisconsin, Madison · Sites in United States
Ages 21+
By country, each count listing its studies:
Of the 134 Smoking Cessation studies recruiting now, 92 (69%) set no upper age limit and 35 (26%) stop at 75 or younger; 6 take children under 18; 40 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 300 is above the median of 163 across 1,425 interventional studies indexed under Smoking Cessation.
Median enrollment 561 across the 32 interventional studies, 16 across the 1 observational. Of the 29 that completed or were terminated, 23 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Wisconsin, Madison is the lead sponsor of 1,190 studies on the registry; 181 are open to participants now.
Of its 157 completed or terminated interventional studies of FDA-regulated products, 118 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 33 studies in Smoking Cessation by University of Wisconsin, Madison, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to investigate how well nicotine pouches and nicotine mini lozenges serve as substitutes for cigarettes when people try to switch from smoking to using these alternate nicotine products.
Participants will:
Researchers currently lack critical data needed to appraise the potential for nicotine pouches to benefit public health. Specifically, they do not know how readily smokers will adopt pouches, how effectively they can substitute for cigarettes when smokers are trying to avoid smoking, the role of nicotine dose in the ability of pouches to serve as a substitute, or the mechanisms that facilitate or hinder successful product transition. This study will address these questions using a 4-arm randomized controlled trial of adults who smoke ≥5 cigarettes daily and are not planning to quit smoking in the next 30 days. This study will provide a rigorous evaluation of the potential efficacy of a relatively modified risk new nicotine product as a substitute for combusted cigarettes. The head-to-head comparison with FDA-approved mini lozenges can inform tobacco regulatory policy decisions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will use 3mg nicotine pouches
Drug: Nicotine Pouches
Participants will use 6mg nicotine pouches
Drug: Nicotine Pouches
Participants will use mini lozenges with dosing based on time to first cigarette (2mg or 4mg)
Drug: Mini Nicotine lozenges
Participants randomized to this arm will use a mint candy during two different 30-minute laboratory sessions only.
nicotine pouches
Also known as: ZYN
mini lozenges
Mean number of cigarettes smoked per day during the 21-day switching period.
Participants will self-report on their cigarette use
Time frame: Baseline to 3 weeks
Change in cigarette craving
Participants will rate their craving for a cigarette using a 0-100 visual analog scale, where 0 = no craving and 100 = extreme craving after sampling their assigned study product after overnight abstinence from smoking
Time frame: Baseline to 3 weeks
Mean units of study product used per day during the 7-days prior to the switching period
Participants will report their study product use via EMA
Time frame: For 7-days leading up to the switching period
Mean units of study product used per day during the 21-day of the switching period
Participants will report their study product use via EMA
Time frame: 21-days of the switching period
Plan to share: No
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Jan 2029, 43 months after the start.
Of 53 non-industry phase 4 interventional studies under Smoking Cessation, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's planned 43 months is above that.
Counting every sponsor, half of 56 studies reached it within 35 months; a quarter within 21 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nicotine Oral Pouch
University of Wisconsin, Madison →